Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Acute Effect of Aclidinium on Hyperinflation and Lung Volume Distribution in Severe COPD Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02181023
• Other study ID #: 960CEC
• Status: Completed
• Phase: Phase 4
• First received: July 1, 2014
• Last updated: October 28, 2014
• Start date: June 2014
• Est. completion date: October 2014

Study information

• Verified date: October 2014
• Source: University of Milan
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

• Chronic Obstructive Pulmonary Disease (COPD) is characterized by lung hyperinflation and flow limitation. These physiopathological modifications are secondary to loss of elastic recoil and bronchial obstruction due to emphysema.

• The cornerstone of COPD treatment is represented by inhaled beta-2 agonists and anticholinergics. The molecules of the latter classes can be characterized by short lasting action (few hours), long acting action (12 hours) or ultra long acting duration of action (24 hours).

• For years the only anticholinergic (or antimuscarinic) drug other than those used by aerosol, was Tiotropium Bromide. Recently two new antimuscarinic agents have been launched on the market: glycopyrronium bromide (once daily) and aclidinium (twice daily).

• The Single Breath Nitrogen Test is capable of identifying the pulmonary closing volume. The part of the curve that reflects lung ventilation inhomogeneity is the slope of phase III

• For COPD patients, the most important characteristic for an inhalatory drug is a prompt action in order to give a quick relief from respiratory symptoms, in particular dyspnoea.

• The objective of this study is to study the acute action of glycopyrronium and aclidinium in terms of reduction of hyperinflation, pulmonary specific resistances, lung volume distribution and dyspnoea at rest in severe COPD patients.

• To our knowledge no study has explored these aspects before.

Description:

Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by progressive and evolutionary physiopathological changes that are responsible for the developing of respiratory symptoms, disability, poor quality of life and morbidity. These changes are secondary to parenchymal disruption and chronic bronchiolar inflammation in major part due to cigarette smoke.

Lung architectural derangement and loss of elastic recoil secondary to emphysema together with decreased internal bronchiolar lumen due to mucosal chronic inflammation are responsible for bronchial obstruction, flow limitation and lung hyperinflation. All these features bring to exertional dyspnoea, chronic cough and sputum and so decreased activeness in daily life activities.

The Single Breath Nitrogen Washout Test (SBN2) is one of the test that more adequately can catch the modifications of small airways and their premature collapse called closing volume (CV). Together with CV the test reflects pulmonary ventilation inhomogeneity through the slope of the so called phase III (a plateau line of nitrogen concentration that is steeper the bigger the ventilation inhomogeneity). In literature the effects of COPD inhalatory treatments on this modifications and on hyperinflation were until today poorly analysed. Recently some new anticholinergic molecules were developed, in particular Aclidinium Bromide and Glycopyrronium Bromide, and there is no trace of such evaluation in medical literature with those new inhalatory drugs.

The study of the acute effects of these drugs on lung mechanics are mandatory because the quicker the effects, the faster the patient's dyspnoea relief.

The study will comprise a first enrollment visit and then the suitable subjects will undergo a pharmacological washout of 72 hours from any inhalatory drug except from Salbutamol.

Then the patients will be randomised to be given Glycopyrronium Bromide 44 mcg (and matched Aclidinium Bromide 322 mcg placebo) or Aclidinium Bromide 322 mcg (and matched Glycopyrronium Bromide 44 mcg placebo) (Day 1) with a double dummy scheme.

At day 1 the pre-dose (baseline) evaluation consists of:

• body plethysmography (with residual volume and specific resistances evaluation),

• arterial blood gas analysis (partial pressure of oxygen and carbon dioxide evaluation),

• SBN2

• Visual Analogic Scale for Dyspnoea (VAS scale) evaluation

• Diffusion Lung Capacity for Carbon Monoxide with Single Breath method (DLCO). These tests will be repeated after 5, 15, 30, 60 and 180 minutes after study drug inhalation. DLCO and arterial blood gas analysis will be performed only at baseline and after 180 minutes after study drug inhalation.

After day 1 all the patients will undergo another period of inhalatory therapy washout of 72 hours (only rescue Salbutamol spray permitted).

After the second pharmacological washout the patients will undergo the crossing over. The ones who were given Aclidinium Bromide will assume Glycopyrronium Bromide and vice versa (Day 2) always in double dummy conditions.

At Day 2 all the patients will undergo the same evaluation as in day 1. At day 1 and day 2 the study drugs with the two different devices (active drug + placebo) will be given to the patients by medical personnel not involved in the performing of any of the tests of day 1 and 2, in order to maintain the double blind conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: October 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

• Signature of informed consent

• COPD patients with age raging from 50 to 85 years old

• Patients with at least a history of COPD of one year

• COPD patients clinically stable in the last three months

• COPD subjects with Forced Expiratory Volume at one second (FEV1)<50% of predicted value

• COPD subjects with Residual Volume (RV) >125% predicted value

• FEV1/Forced Vital Capacity (FVC) <88% (males) or <89% (females) of Low Levels of Normality (LLN)

• COPD former or active smokers with at least a smoking history of 20 pack year

Exclusion Criteria:

• Acute Bronchial Exacerbation at recruitment

• Fertile women with age between 18 and 50 years old or with active period

• Pregnancy

• Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment.

• FEV1/FVC more than 70% of predicted value in basal conditions

• FEV1 more than 70% of predicted value in basal conditions

• Known deficit of alpha 1 antitrypsin

• Subjects that underwent a Lung Volume Reduction Surgery (LVRS)

• Subjects with known positivity to Human Immunodeficiency Virus (HIV)

• Misuse of alcool or drugs

• Lack of compliance in performing respiratory tests

• Subjects not capable to follow the study prescriptions because of psychic disorders or language problems.

• Long Term Oxygen Therapy with flows > 6 litres per minute (l/min) at rest

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Aclidinium Bromide
Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
• Glycopyrronium Bromide
Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom

Locations

Country	Name	City	State
Italy	Fondazione Salvatore Maugeri	Milan

Sponsors (2)

Lead Sponsor	Collaborator
University of Milan	Fondazione Salvatore Maugeri

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Specific AirWay Resistances (sRAW) variation from baseline	Specific AirWay Resistances (sRAW) are calculated from body plethysmography before study drug inhalation (baseline), and again 5, 15, 30,60 and 180 minutes after inhalation of study drug. The same subject will undergo the same evaluation in the second part of the study, after the crossing over	At baseline, 5, 15, 30, 60 and 180 minutes after study drug administration	No
Primary	Residual Volume Variation from baseline	Residual Volume is obtained by performing body plethysmography before study drug inhalation (baseline), and again 5, 15, 30,60 and 180 minutes after inhalation of study drug. The same subject will undergo the same evaluation in the second part of the study, after the crossing over	At baseline, 5, 15, 30, 60 and 180 minutes after study drug administration	No
Primary	Functional Residual Capacity variation from baseline	Functional Residual Capacity (plethysmographic Intra Thoracic Gas Volume - ITGV) is obtained by performing body plethysmography before study drug inhalation (baseline), and again 5, 15, 30,60 and 180 minutes after inhalation of study drug. The same subject will undergo the same evaluation in the second part of the study, after the crossing over	At baseline, 5, 15, 30, 60 and 180 minutes after study drug administration	No
Secondary	Phase III slope variation from baseline	Phase III slope is measured from the Single Breath Nitrogen Washout curve. It is measured at baseline (before study drug administration, and after 5, 15, 30, 60 and 180 minutes after study drug administration. The same patient will perform the same evaluation after drug crossing over	At baseline, 5, 15, 30, 60 and 180 minutes after study drug administration	No
Secondary	Visual Analogical Scale (VAS) for Dyspnoea at rest variation from baseline	Visual Analogical Scale (VAS) for Dyspnoea is obtained by asking the patients to evaluate the intensity of dyspnoea sensation at rest putting a sign in a scale that ranges from 0 to 10, being 10 the maximum dyspnoea discomfort and 0 the absence of dyspnoea sensation. The VAS scale will be performed before study drug inhalation (baseline), and again 5, 15, 30,60 and 180 minutes after inhalation of study drug. The same subject will undergo the same evaluation in the second part of the study, after the crossing over.	At baseline, 5, 15, 30, 60 and 180 minutes after study drug administration	No
Secondary	Oxygen and Carbon Dioxide variation from baseline	Partial Pressure of Oxygen (PaO2) and Partial Pressure of Carbon Dioxide (PaCO2) are obtained from arterial blood gas analysis before study drug inhalation and 180 minutes after drug inhalation. Patients will undergo the same evaluation after drug crossing over	At baseline and 180 minutes after inhalation of study drug	No